🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 15 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 29/09/1997 | 18,38 | 19,44 | 18,38 | 19,44 | +5,60% | 5,78% | 378.000 |
| 26/09/1997 | 18,38 | 18,69 | 18,25 | 18,41 | -0,17% | 2,38% | 430.000 |
| 25/09/1997 | 19,00 | 19,13 | 18,00 | 18,44 | -4,84% | 5,92% | 737.800 |
| 24/09/1997 | 19,63 | 20,00 | 18,25 | 19,38 | -2,67% | 8,92% | 1.004.200 |
| 23/09/1997 | 20,25 | 20,44 | 19,75 | 19,91 | -1,70% | 3,40% | 551.800 |
| 22/09/1997 | 20,13 | 20,25 | 19,94 | 20,25 | +1,57% | 1,55% | 186.000 |
| 19/09/1997 | 19,56 | 20,13 | 19,19 | 19,94 | -0,31% | 4,79% | 512.000 |
| 18/09/1997 | 19,13 | 20,50 | 18,81 | 20,00 | +5,26% | 8,82% | 1.733.600 |
| 17/09/1997 | 17,81 | 19,13 | 17,81 | 19,00 | +5,74% | 7,37% | 1.569.200 |
| 16/09/1997 | 17,94 | 18,19 | 17,63 | 17,97 | +0,17% | 3,14% | 345.800 |
| 15/09/1997 | 17,94 | 17,94 | 17,75 | 17,94 | +0,00% | 1,05% | 210.000 |
| 12/09/1997 | 17,81 | 18,00 | 17,69 | 17,94 | +1,41% | 1,75% | 736.800 |
| 11/09/1997 | 17,63 | 17,94 | 17,50 | 17,69 | -0,70% | 2,48% | 323.000 |
| 10/09/1997 | 18,06 | 18,06 | 17,44 | 17,81 | -1,38% | 3,46% | 456.000 |
| 09/09/1997 | 18,06 | 18,06 | 17,88 | 18,06 | +0,70% | 1,04% | 245.800 |
| 08/09/1997 | 18,19 | 18,19 | 17,63 | 17,94 | -0,35% | 3,09% | 243.400 |
| 05/09/1997 | 17,69 | 18,13 | 17,56 | 18,00 | +2,49% | 3,18% | 203.000 |
| 04/09/1997 | 18,00 | 18,00 | 17,44 | 17,56 | -2,09% | 3,13% | 217.400 |
| 03/09/1997 | 17,56 | 17,94 | 17,38 | 17,94 | +1,77% | 3,20% | 584.000 |
| 02/09/1997 | 17,25 | 17,75 | 17,00 | 17,63 | +2,92% | 4,35% | 579.000 |
| 29/08/1997 | 16,63 | 17,19 | 16,50 | 17,13 | +2,05% | 4,14% | 396.000 |
| 28/08/1997 | 16,44 | 17,00 | 16,13 | 16,78 | +2,48% | 5,32% | 316.600 |
| 27/08/1997 | 16,00 | 16,38 | 16,00 | 16,38 | +1,55% | 2,34% | 131.200 |
| 26/08/1997 | 16,75 | 17,13 | 16,00 | 16,13 | -4,80% | 6,72% | 356.200 |
| 25/08/1997 | 16,38 | 16,94 | 16,25 | 16,94 | +3,44% | 4,20% | 394.000 |
| 22/08/1997 | 15,50 | 16,44 | 15,13 | 16,38 | +1,55% | 8,47% | 465.800 |
| 21/08/1997 | 16,75 | 16,88 | 15,88 | 16,13 | -4,44% | 5,97% | 461.200 |
| 20/08/1997 | 16,56 | 17,06 | 16,38 | 16,88 | +3,85% | 4,15% | 611.800 |
| 19/08/1997 | 15,72 | 16,44 | 15,63 | 16,25 | +4,00% | 5,17% | 530.800 |
| 18/08/1997 | 15,69 | 15,72 | 15,00 | 15,63 | +0,40% | 4,58% | 343.600 |